Article
Effects of CYP2C9 polymorphisms on the pharmacokinetics of R- and S-phenprocoumon in healthy volunteers.
Pharmacogenetics - 1 Jan 2004
Kirchheiner Julia, Ufer Mike, Walter Ev-Charlotte, Kammerer Bernd, Kahlich Rainer, Meisel Christian, Schwab Matthias, Gleiter Christoph H, Rane Anders, Roots Ivar, Brockmöller Jürgen
Abstract excerpt
CYP2C9 catalyses the biotransformation of the oral anticoagulants S-warfarin and R- and S-acenocoumarol. According to data obtained in vitro, phenprocoumon is also metabolized by CYP2C9 but the impact of the CYP2C9 polymorphism on phenprocoumon pharmacokinetics has not been studied. Twenty-six healthy heterozygous and homozygous carriers of the CYP2C9 alleles *1 (wild-type), *2 (Arg144Cys), and *3 (Ile359Leu)...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.